TY - JOUR AB - The present study aimed to examine the effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer's disease (AD). For this purpose, a total of 126 patients with AD admitted to Luoyang Central Hospital from January, 2018 to December, 2018 were enrolled. Patients were divided into different groups according to the treatment they selected. Patients treated with single‑agent donepezil were separated into a monotherapy group (n=56), and patients receiving donepezil plus rivastigmine were placed in the combination group (n=70). Before and after treatment, the cognitive functions, mental behavior and quality of life of the patients in the two groups were respectively evaluated by the Alzheimer's Disease Assessment Scale‑Cognitive Subscale (ADAS‑Cog), the Mini‑Mental State Examination (MMSE), the Blessed‑Roth Dementia Scale (BRDS) and the QOL‑AD. In addition, the serum bradykinin level was detected by enzyme‑linked immunosorbent assay. Following treatment, the MMSE score, BRDS, ADAS‑Cog and QOL‑AD scores were improved compared with those before treatment (P<0.05). However, following treatment, the 4 scores in the combination group were significantly higher than those in the monotherapy group (P<0.05). No significant differences were observed in the incidence of adverse reactions between the 2 groups (P>0.05). Following treatment, the bradykinin level in both groups was significantly decreased (P<0.05), although the decrease in the combination group was more significant than that in the monotherapy group (P<0.05). On the whole, the findings of the present study indicate that rivastigmine hydrogen tartrate used in combination with donepezil hydrochloride relieves the symptoms and improves the quality of life of patients with AD more effectively, which may be related to the reduction of the bradykinin level in these patients. AD - Department of Rehabilitation, Luoyang Central Hospital, Luoyang, Henan 471000, P.R. China Department of Neurology, Luoyang Central Hospital, Luoyang, Henan 471000, P.R. China AU - Zhang,Xiaohong AU - Yu,Ronghua AU - Wang,Huilin AU - Zheng,Ruifeng DA - 2020/08/01 DO - 10.3892/etm.2020.8872 EP - 1795 IS - 2 JO - Exp Ther Med KW - rivastigmine hydrogen tartrate donepezil hydrochloride Alzheimer's disease bradykinin cognitive function PY - 2020 SN - 1792-0981 1792-1015 SP - 1789 ST - Effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer's disease T2 - Experimental and Therapeutic Medicine TI - Effects of rivastigmine hydrogen tartrate and donepezil hydrochloride on the cognitive function and mental behavior of patients with Alzheimer's disease UR - https://doi.org/10.3892/etm.2020.8872 VL - 20 ER -